Clinical Trial Update: Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating anlotinib in combination with irinotecan for esophageal squamous cell carcinoma is underway, with status not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Irinotecan (Irinotecan)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN